echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur Urol Oncol: Intravesical VPM1002BC for non-muscle-invasive bladder cancer (NMIBC) recurrence after conventional BCG therapy

    Eur Urol Oncol: Intravesical VPM1002BC for non-muscle-invasive bladder cancer (NMIBC) recurrence after conventional BCG therapy

    • Last Update: 2022-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Over time, Bacille Calmette-Guérin (BCG) has evolved into different types and is used in intravesical immunotherapy for non-muscle-invasive bladder cancer (NMIBC)


    Some comparative clinical studies have shown differences in therapeutic effect between selected strains

    VPM1002BC is a transgenic M.


    To investigate the efficacy, safety, tolerability and quality of life of recurrent non-muscle invasive bladder cancer (NMIBC) after intravesical injection of VPM1002BC in the treatment of conventional BCG therapy.


    The researchers designed a phase 1/2 single-arm trial (NCT02371447)


    After excluding 2 ineligible patients, 40 patients were included in the full analysis group


    Relapse-free rate at 60 weeks of treatment

    Relapse-free rate at 60 weeks of treatment

    In conclusion, almost half of the patients did not relapse after treatment with VPM100BC 1 year after the start of treatment


    Almost half of the patients did not relapse after treatment with VPM100BC 1 year after the start of treatment Almost half of the patients did not relapse after treatment with VPM100BC 1 year after the start of treatment

     

    Original source:

    Original source:

    Cyrill A Rentsch, George N Thalmann, Ilaria Lucca et al.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.